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Mycobacterium tuberculosis infection and inflammation: what 
is beneficial for the host and for the bacterium?
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Tuberculosis is still a major health problem in the world. Initial interactions between Mycobacterium 
tuberculosis and the host mark the pathway of infection and the subsequent host inflammatory 
response. This inflammatory response is tightly regulated by both the host and the bacterium 
during different stages of infection. As infection progresses, the initial intense pro-inflammatory 
response observed is regulated by suppressive mediators balancing inflammation. In this 
environment, M. tuberculosis battles to survive interfering with the host inflammatory response. 
In this review we discuss the major effector molecules involved in inflammation in relation to 
the different stages of M. tuberculosis infection.
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infection depends partially on the genetics of the human popula-
tion (i.e., defined by the intrinsic microbicidal capacity of host 
phagocytes) and also on the inhaled M.tb strain (i.e., defined by 
innate virulent factors in each M.tb strain). In the primary infec-
tion M.tb multiplies in the lungs and causes mild inflammation. 
Although AMs are thought to be an effective barrier to contain 
pathogens, M.tb has evolved various mechanisms to evade the 
host immune response and survive in these cells. These survival 
mechanisms include triggering an anti-inflammatory response, 
blocking reactive oxygen and nitrogen intermediate (ROIs and 
RNIs, respectively) production, and reducing the acidification of 
the M.tb-containing phagosome (Flynn and Chan, 2001; Fenton 
et al., 2005; Cooper, 2009).
The next stage of infection is characterized by the emergence 
of  cell-mediated  immunity  and  the  formation  of  granulomas 
(described below). M.tb bacilli that escape the bactericidal effects 
of the AM, will multiply and result in destruction of AMs. This will 
in turn attract blood monocytes and other inflammatory cells (i.e., 
neutrophils) to the site of infection. Monocytes mature to become 
antigen presenting AMs and DCs and ingest, but not effectively kill 
the bacteria. At this stage, M.tb grows under limited tissue damage. 
By 6–8 weeks post-infection, antigen presenting DCs have traveled 
to lymph nodes where T lymphocytes are activated and recruited. 
Activated T lymphocytes that migrate to the site of infection prolifer-
ate forming an early stage granuloma, where macrophages become 
activated to kill intracellular M.tb (Ulrichs and Kaufmann, 2006). 
However, continuing T cell activation leads to formation of granu-
lomas that mark the persistence stage of the infection (latency), 
where the growth and spread of bacteria into additional tissue sites 
are limited. At this stage more than 90% of infected people remain 
asymptomatic, but M.tb may survive within AMs.
IntroductIon
Over the past 15 years as a result of a rigorous approach to treatment 
endorsed by the World Health Organization, close to 36 million 
people have been cured of tuberculosis (TB). However, although 
a great deal of effort has occurred for handling the TB pandemic 
around the world, there are still 1.8 million people dying from TB 
each year. Indeed, there are too many inherent factors involved in 
the surveillance of Mycobacterium tuberculosis (M.tb, the etiological 
agent of TB) including the nature of the spread of M.tb infection, 
the difficultly in obtaining the right drug treatment, and a complex 
therapeutic regime which still makes TB one of the major health 
challenges in the world. HIV and M.tb co-infection and the emer-
gence of multi-drug and extensively drug resistant strains of M.tb 
are also adding to the burden of TB clinical cases in the world.
Tuberculosis  pathogenesis  is  driven  by  a  complex  interplay 
between the host immune system and the survival strategies of the 
bacterium. The inflammatory response to M.tb infection is tightly 
regulated by both the host and the bacterium. The primary goal of 
this review is to discuss the major effector molecules involved in 
inflammation in relation to the different stages of M.tb infection.
StageS of MycobacteriuM tuberculosis InfectIon
Mycobacterium tuberculosis is mainly considered to be an airborne 
pathogen. The infection process of M.tb can be divided into three 
different but interrelated stages. The first stage is the aerosol trans-
mission of droplets containing M.tb from an infected individual 
to a healthy individual. Once within the lungs, M.tb enters and 
resides within alveolar macrophages (AMs) and dendritic cells 
(DCs; Cooper, 2009). Though the AM ingests bacilli and often 
kills them, the bactericidal capacity of the AM is still not very well 
defined. In a given M.tb infection, the initial containment of the Frontiers in Microbiology  |  Cellular and Infection Microbiology    January 2011  | Volume 2  | Article 2  |  2
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Production of IL-12 (Seder et al., 1993) and IL-23 (Oppmann et al., 
2000) by DCs primes the Th1 T cell response, which is important for 
granuloma assembly. This flow of inflammatory events is regulated 
by the production of IFN-γ and IL-2 by activated T cells that reach 
the infection site (Cooper, 2009). Studies using CD4 deficient mice 
demonstrate that CD4 T cells are required for the recruitment of 
mononuclear cells to the infection site and the organization that 
is required for the long term survival of the host (Saunders and 
Cooper, 2002). Along with CD4 T cells, CD8 T cells (Saunders and 
Britton, 2007) and CD1-restricted NKT-cells (Chackerian et al., 
2002; Co et al., 2004) are also key components of developing granu-
loma. A significant characteristic common between mouse and 
human pulmonary TB is also the presence of B-cell lymphocyte 
clusters (Turner et al., 2001; Ulrichs et al., 2004; Tsai et al., 2006). 
Later studies indicate that B-cell aggregates may serve different 
purposes in both species as in mice macrophages encircle B-cells; 
however, in humans B-cell aggregates recruit T cells that are evenly 
distributed in the clusters (Tsai et al., 2006). Interestingly, studies 
looking at the ratio between the necrotic core and the neighboring 
layers of dense leukocytes suggest that the necrotic core expands at 
the expense of the surrounding layers of cells and not because of 
leukocyte infiltration (Ulrichs and Kaufmann, 2006).
Although it seems contradictory, it is understood that the initial 
inflammatory response to M.tb is crucial for granuloma generation 
but also for M.tb long term survival within the host. In this context, 
pro-inflammatory cytokines reduce the bacterial burden, regulating 
the activity of other cytokines and chemokines, and generating and 
maintaining organized granulomas. Infection of macrophages by 
M.tb primarily induces the production of TNF, IFN-γ, IL-12, and 
RNIs and ROIs (Flynn and Chan, 2001; Cooper, 2009), which are 
considered to be key regulatory factors in the formation and/or 
maintenance of the granuloma structure. The importance of TNF 
in granuloma formation has been shown by using TNF neutralizing 
antibodies and TNF deficient mice in vivo. These studies showed that 
TNF and its receptor are critical in granuloma formation and subse-
quent protection against M.tb infection, as well as their involvement 
in RNI production by macrophages during early infection (Flynn 
et al., 1995a; Kaneko et al., 1999). TNF can also induce macrophages 
to release chemokines that guide cells to the site of infection and 
prevent their migration away from the site (Flynn and Chan, 2005). 
Recent studies performed in Cynomolgus macaques using TNF neu-
tralizing drugs before M.tb infection demonstrated uncontrolled, 
disseminated infection by 8 weeks of infection. This lack of TNF also 
induced a high rate of reactivation TB among macaques with latent 
infection. Importantly, the granuloma architecture in non-human 
primates after treatment with neutralizing TNF agents was similar 
to that seen in active TB in humans (Capuano III et al., 2003; Lin 
et al., 2010). Histological studies performed on human lung biopsies 
from patients receiving TNF blockade reconfirm the role of TNF in 
granuloma formation by showing granuloma disorganization due to 
extensive lymphocytic infiltrations (Keane et al., 2001; Figure 1C). 
In addition to TNF, IFN-γ is also important in the development of 
granulomas (Flynn et al., 1993). IFN-γ deficient mice were found to 
be incapable of developing granulomas following aerosol infection 
and their lungs were found to be infiltrated with neutrophils result-
ing in cellular necrosis instead of granuloma formation (Cooper 
et al., 1993; Pearl et al., 2001; Figure 1D).
The third and final stage is when latent and controlled M.tb 
infection is reactivated. There are two main reasons described for 
a reactivation event to occur, a decline in the host’s immunity due 
to genetic or environmental cause; and a failure to develop and 
maintain immune signals. Under these circumstances, the granu-
loma structure disrupts and results in lung cavitation and pul-
monary disease (Kaplan et al., 2003; Dheda et al., 2005; Ulrichs 
and Kaufmann, 2006; Russell, 2007). Among the genetic causes 
described that make a subject susceptible to TB are mutations in 
specific host C-type lectins, cytokines, chemokines, and their spe-
cific receptors disrupting critical signaling pathways involved in the 
immune response against M.tb. Compromised immune surveillance 
for reasons such as co-infection with HIV, where a host becomes 
immuno-  compromised especially for CD4 T cells (the cell target for 
HIV), is the most important environmental or exogenous cause of 
susceptibility to TB (Geldmacher et al., 2010). The reactivation of 
M.tb infection can also be due to changes in host cytokine/chem-
okine networks, implicated in the inflammatory response against 
M.tb infection, that are a consequence of stress and/or old age 
(Turner, 2011). Earlier studies have also suggested that exogenous 
re-infection with another strain of M.tb (Sonnenberg et al., 2001; 
Behr, 2004) is an additional factor leading to active disease.
development of the M.tb granuloma
The hallmark in M.tb infection is the presence of granulomas within 
the lung. From the perspective of the bacterium, M.tb-induced 
granulomas are a collection of well organized immune cells that 
provide a safe microenvironment to establish latency. From the 
host perspective, granuloma formation restricts the spread of M.tb 
infection. The formation of a granuloma starts with a transient 
influx of neutrophils to the site of the infection, followed by acti-
vated macrophages and lymphocytes (reviewed in detail in Ulrichs 
and Kaufmann, 2006; Russell, 2007). An established granuloma is 
composed of infected AMs and epithelioid cells that form a necrotic 
central core which provides nutritional support to M.tb. The central 
necrotic core of the granuloma is composed by both host and M.tb 
factors. Surrounding this necrotic center there are activated macro-
phages and layers of CD4+ and CD8+ T cells defining a dense cellular 
wall that restricts the spread of the M.tb (Saunders and Cooper, 
2002). In immunocompetent M.tb-infected people (Figure 1A), 
M.tb-containing granulomas are small, compact, and characterized 
by the presence of a large number of IFN-γ CD4-T cells; however, 
in immunodeficient M.tb-infected people (Figure 1B), granulomas 
are characterized by being large, rich in activated macrophages, 
and with few surrounding lymphocytes (Ulrichs et al., 2005). The 
main cause for tissue injury and clinical manifestation is the pres-
ence of large caseating granulomas and fibrotic scarring due to 
granulomatous inflammation (Daley, 2010); where the host Th1 
response serves to try to contain the infection and prevent the 
development of active disease yet cannot eliminate M.tb (Saunders 
et al., 1999).
The mechanism and the products influencing granuloma forma-
tion are not very well established. In response to M.tb interaction 
with AMs and DCs, there is a release of inflammatory cytokines 
such as tumor necrosis factor-α(TNF), interleukin-(IL)-12, and 
IL-23 along with a variety of chemokines including (C-C) motif 
ligand 2 (CCL2), CCL5, and (C-X-C) motif ligand 8 (CXCL8). www.frontiersin.org  January 2011  | Volume 2  | Article 2  |  3
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The exact role of chemokines in granuloma formation is still not 
very clear. Studies have shown some role for CC chemokine subfamily 
members particularly CCL5, CCL10, and CCL21 in   granuloma for-
mation (Mendez-Samperio, 2008). In vivo studies using mice have 
established that there is a certain level of redundancy in this model 
system. More recent studies showed the importance of CCL5 and CCL4 
and their receptors in the establishment of early granulomas in mice 
by directly controlling the migration of IFN-γ positive CD4 T cells to 
the site of the infection (Vesosky et al., 2010). However in humans, 
chemokines like CCL2, CCL5, and CXCL10 may participate in the 
protection mechanism against M.tb infection (Algood et al., 2003).
Inflammasome-related cytokines like IL-1β (Juffermans et al., 
2000; Sugawara et al., 2001) and IL-18 (Sugawara et al., 1999; 
Schneider et al., 2010) have also been shown to be involved in 
promoting granuloma formation and organization. In this con-
text, the apoptotic speck-like protein containing a CARD domain 
(PYCARD), defined as an adaptor protein involved in IL-1β and 
IL-18 activation through caspase-1 processing, has been shown 
to play a major role in maintaining granuloma integrity during 
chronic M.tb infection (McElvania et al., 2010).
hoSt receptorS and InflammatIon In M.tb InfectIon
The initial interaction between M.tb and the host dictates the path-
way and outcome of infection (Figure 2). On the host side, there 
are specific receptors capable of recognizing M.tb. Normally this 
Interleukin-12 is also related to granuloma formation by promot-
ing the Th1 response and inducing IFN-γ positive CD4 T cells (Seder 
et al., 1993). Studies in mice established that neutralization of IL-12 
by specific monoclonal antibodies results in a reduction in granuloma 
integrity and slowing of the capacity of the animal to control M.tb 
growth (Cooper et al., 1995; Figure 1E). Later human studies cor-
roborated the importance of IL-12 in granuloma maintenance, where 
specific mutations in either the IL-12 p40 or IL-12Rβ1 (IL-12 recep-
tor) gene showed reduced levels of IL-12 and IL-23, and subsequent 
low IFN-γ induced T cell responses in subjects susceptible to myco-
bacterial infections (Remus et al., 2001; Fieschi and Casanova, 2003). 
Other cytokines have also been implicated in the establishment of the 
granuloma; however, their specific role is still uncertain. This is the 
case for IL-10, where recent in vivo studies using mice over-expressing 
human IL-10 in their lungs found an increase in macrophage presence 
and bacterial burden in M. avium-containing granulomas (Feng et al., 
2002; Figure 1F). This was related to a decrease in the levels of pro-
inflammatory cytokines like TNF and IL-12 indicating that IL-10 may 
employ a suppressive effect on the control of mycobacterial infection 
by negatively controlling macrophage activation. Another regulatory 
molecule that has been indirectly implicated in granuloma formation 
is IL-27, which has been shown to activate naïve T cells after their 
encounter with macrophages and DCs (Owaki et al., 2005). In this 
context, IL-27 deficient mice have severe lung pathology due to the 
uncontrolled spread of M.tb infection (Holscher et al., 2005).
Figure 1 | granuloma formation. Schematics of lesion structure at each 
stage of granuloma formation in immunocompetent (A) or immunodeficient 
(B) M.tb-infected people. Once M.tb reaches the lungs, bacilli are internalized by 
AMs triggering the subsequent inflammatory response. In the early stage, the 
granuloma has a core of infected macrophages enclosed by mononuclear 
phagocytes, surrounded by lymphocytes. In the case of immunocompetent 
people, infection will be contained within small and compact granulomas 
characterized by the presence of a large number of IFN-γ CD4 T cells. For 
immunodeficient people, as the granuloma matures, it is characterized by being 
rich in activated macrophages and with few surrounding lymphocytes. Over time 
the granuloma caseous necrotic center liquefies and cavitates, spilling 
thousands of infectious M.tb bacilli into the airways. (C–F) Schematic of 
granulomas developed in the absence or presence of the main inflammatory 
mediators described in M.tb pathogenesis.Frontiers in Microbiology  |  Cellular and Infection Microbiology    January 2011  | Volume 2  | Article 2  |  4
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observed via TLR2 signaling is mediated through its adaptor pro-
tein MyD88 (Quesniaux et al., 2004), where engagement of TLR2 
triggers a nuclear factor kappa-light chain-enhancer of activated 
B-cell (NFκB) signaling cascade through the recruitment of MyD88 
and TIRAP (toll-interleukin 1 receptor [TIR] domain containing 
adaptor protein; Kawai and Akira, 2010). Of no surprise is that 
the response observed depends on the mycobacterial ligand and 
the nature of the host cell type studied. As an example, uncapped 
AraLAM was shown to induce cell activation via TLR2 (Underhill 
et al., 1999) leading to M.tb killing in both murine and human 
macrophages but in a nitric oxide dependent and independent 
manner, respectively (Thoma-Uszynski et al., 2001).
Interestingly, an overwhelming stimulation of the TLR2 pathway 
may also be advantageous for M.tb. Recent studies have indicated 
that prolonged TLR2 signaling induced by M.tb lipoproteins LpqH, 
LpRG, and LpRA inhibit the expression of major histocompatibility 
complex (MHC) class II thereby decreasing antigen presentation 
in macrophages infected with M.tb (Harding and Boom, 2010). 
Related to this, more recent studies using mice also suggest that 
TLR2 may be one of many pathways exploited by M.tb to inhibit 
MHC-I antigen cross processing and presentation to CD8+ T cells 
(Harding and Boom, 2010). Studies performed on infected DCs 
also resulted in TLR2-dependent inhibition of TLR9-dependent 
IFN-α/β expression, leading to a decrease in induction of IFN-α/β-
dependent MHC-I cross processing (Simmons et al., 2010). In this 
regard, during M.tb infection in vivo, it is still uncertain whether 
TLR2  dependent  inhibition  of  the  TLR9/IFN-α/β-dependent 
MHC-I processing pathway is of benefit to the host by limiting the 
harmful effects of excessive inflammation or to M.tb, as it may pro-
vide a path for M.tb to escape the host immune response. Overall, 
a negative regulatory feedback mechanism among TLR signaling 
networks during M.tb chronic infection may benefit the host by 
preventing detrimental effects of excessive inflammation (Simmons 
et al., 2010). In this context, studies performed to understand the 
role of TLR signaling in vivo using TLR deficient mice indicate 
recognition is beneficial for the host by activating innate immunity; 
however, there are specific receptors that favor M.tb uptake, bypass-
ing the pro-inflammatory response and leading to intracellular 
survival. In this section we will discuss host receptors involved in 
M.tb recognition and the subsequent inflammatory response.
toll-lIke receptorS
Toll-like receptor (TLR) signaling is essential for immunity to vari-
ous intracellular pathogens. TLRs are a set of pattern recognition 
receptors (PRRs) that are expressed on many cell types but their 
function on antigen presenting cells (APCs) is particularly impor-
tant (reviewed in Kawai and Akira, 2010). On macrophages TLRs 
are either expressed on the surface (like TLR2 and 4) or inside cell 
compartments (like TLR8 and 9; Kawai and Akira, 2010). TLRs 
detect a wide range of structures on M.tb (Figure 2), which aid in 
the activation of innate immunity and enhance adaptive immunity 
by mediating the secretion of various pro-inflammatory cytokines 
along with other anti-bacterial effector molecules. The relationship 
between TLRs and M.tb is a bit more complex than with other bac-
teria. Various studies performed indicate that different components 
of the bacteria interact with different TLRs. Among TLRs the key 
players in TB immunity are TLR2 (alone or as a heterodimer with 
TLR1 or TLR6), TLR9, and probably TLR4 (Harding and Boom, 
2010). For TLR2 alone or in association with TLR1 or TLR6, several 
groups have reported a strong pro-inflammatory response induced 
by mycobacterial cell wall components. This is the case for the 
19 KDa lipoprotein, phospho-myo-inositol-capped or non-capped 
lipoarabinomannan (PILAM and AraLAM respectively, both pro-
duced by less pathogenic mycobacteria), lower- and higher-order 
phosphatidyl-myo-inositol mannosides (PIM1, PIM2, and PIM6 
families), lipomannan, and trehalose dimycolate (reviewed in Jo 
et al., 2007). A combination of studies using several M.tb ligands 
and mouse macrophages deficient in TLR2 and MyD88 (myeloid 
differentiation primary-response protein 88) determined conclu-
sively that the strong pro-inflammatory response to M.tb infection 
Figure 2 | Antigen presenting cell receptors involved in M.tb infection. M.tb 
cell wall components associate with a subset of immune receptors initiating 
phagocytosis and mediating specific host cell responses. Interactions with certain 
receptors or soluble collectins lead to the activation of pro-/anti-inflammatory 
responses in the host that may influence the intracellular survival of M.tb. TLR, 
Toll-like receptor; MR, mannose receptor; DC-SIGN, dendritic cell-specific 
intercellular adhesion molecule-3 grabbing non-integrin; CR, complement receptor; 
SP-A and SP-D, surfactant protein-A and -D; MBL, mannose binding lectin; 
Dectin-1, dendritic cell-associated C-type lectin-1; Mincle, macrophage-inducible 
C-type lectin; NOD-2, nucleotide-binding oligomerization domain-like receptor 2.www.frontiersin.org  January 2011  | Volume 2  | Article 2  |  5
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inflammatory response. PPAR-γ up-regulation via the MR leads to 
the simultaneous increase in the production of IL-8 (or CXCL-8), 
expression of cyclooxygenase 2 (COX2), and production of pros-
taglandin 2 (PGE2; Rajaram et al., 2010). This study also revealed 
that PPAR-γ deficiency in human macrophages leads to increased 
levels of TNF and decreased bacterial load, indicating that the MR 
negatively regulates protective macrophage inflammatory responses 
to M.tb infection. In murine macrophages, inhibition of PGE2 by 
M.tb infection prevents apoptosis and leads the infected cell to a 
necrotic pathway favoring the spread of the infection (Divangahi 
et al., 2010). In these type of studies we should carefully consider 
differences between mouse and human macrophages as well as the 
existence of receptor-dependent/specific regulatory mechanism(s) 
in these complex signaling networks. In this context, in addition to 
M.tb ManLAM blocking TNF production via the MR, unpublished 
data by Rajaram and Schlesinger identify a novel molecular and 
cellular mechanism underlying the ability of another major M.tb 
cell wall component, LM, to block TLR2 induced biosynthesis of 
TNF in macrophages, thereby allowing M.tb to subvert the host 
immune response and potentially increase its virulence (personal 
communication).
dendrItIc cell-SpecIfIc Icam-3-grabbIng non-IntegrIn
Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN) 
expressed on DCs (Geijtenbeek et al., 2000), strongly binds to 
M.tb through its surface-exposed mannose-containing molecules 
ManLAM, LM, and PIMs (reviewed in Ehlers, 2009). Recently, 
α-glucan found on the M.tb surface was also found to act as a 
ligand for DC-SIGN (Geurtsen et al., 2009). DC-SIGN actively 
participates in the phagocytosis of M.tb by DCs leading to bac-
terial killing by acidification of the M.tb-containing phagosome 
(Geijtenbeek et al., 2003) (Figure 2). However, the role of DC-SIGN 
in inflammation is controversial. Association of M.tb, α-glucan or 
its mannosylated cell wall components with DC-SIGN has been 
shown to induce production of anti-inflammatory mediators like 
IL-10 (Ehlers, 2009; Geurtsen et al., 2009). Recent in vivo studies 
using wild-type mice expressing human DC-SIGN homologs (Park 
et al., 2001; McGreal et al., 2005; Powlesland et al., 2006) or trans-
genic mice expressing human DC-SIGN, consider the possibility 
that DC-SIGN may act to dampen the immune response thereby 
promoting host protection by limiting tissue damage (Wieland 
et al., 2007; Schaefer et al., 2008; Tanne et al., 2009). Conversely, 
using genetically engineered M. marinum strains lacking essen-
tial mannosylated components on their cell surface revealed that 
the ManLAM–PIM/DC-SIGN pathway may not be significantly 
involved in the regulation of cytokine secretion (Appelmelk et al., 
2008). However, as M. marinum does not reflect the overall man-
nosylation pattern observed in M.tb laboratory strains (where 
M.tb clinical isolates also present different degrees of mannosyla-
tion; Torrelles et al., 2008b), the direct functional consequences of 
DC-SIGN ligation in M.tb pathogenesis are still unclear.
complement receptorS
Complement receptors (CRs) are expressed on all mononuclear 
phagocytes and mediate the phagocytosis of a diverse group of 
intracellular pathogens. Several studies have established the role 
of C3 opsonization and the contribution of CR1, CR3, and CR4 
that a balance in the TLR signaling network is necessary to control 
inflammation. This is indicated by studies where the exclusion of 
the TLR2 signaling pathway with a moderate dose of M.tb in vivo 
results in an exaggerated inflammatory response which may be 
detrimental for the host (Drennan et al., 2004).
TLR9 recognizes unmethylated CpG (cytosine phosphate gua-
nosine motif) found in mycobacterial DNA (Kawai and Akira, 
2010). As mentioned above, activation of TLR9 induces IFNα/β 
and  MHC-I  antigen  cross  processing  (Simmons  et  al.,  2010). 
Mycobacterial ligands for TLR4 are still undetermined; although 
recently, recombinant M.tb heat shock protein (hsp) 65 has been 
described as a ligand for TLR4 inducing NFκB via MyD88, TIRAP, 
TRIF  (TIR-domain-containing  adapter-inducing  interferon-β), 
and TRAM (TRIF-related adaptor molecule)-dependent signal-
ing pathways (Bulut et al., 2005). Studies using TLR4 deficient 
mice  infected  with M.  bovis  Bacillus  Calmette–Guérin  (BCG), 
showed that these mice are capable of controlling the infection; 
however, mice eventually showed body weight loss and increased 
local inflammation indicating that TLR4 plays a defined role in 
modulating inflammation in mycobacterial infections (Fremond 
et al., 2003).
the mannoSe receptor
The cell envelope of pathogenic mycobacteria like M.tb is par-
ticularly  rich  in  mannose-containing  biomolecules,  including 
ManLAM, LM, higher-order PIMs, arabinomannan, mannan, and 
mannosylated glycoproteins. ManLAM, LM, and higher-order PIMs 
are incorporated into the M.tb plasma membrane and also exposed 
on its cell surface acting as ligands for host cell receptors contribut-
ing to the pathogenesis of M.tb (Torrelles and Schlesinger, 2010). 
ManLAM and higher-order PIMs contain terminal mannosyl units 
ideally located to interact with the MR on macrophages and DCs 
(Schlesinger et al., 1994; Torrelles and Schlesinger, 2010; Figure 2). 
The MR is defined as a homeostatic/clearance/immunomodula-
tory receptor for endogenous serum glycoproteins with N-linked 
high-mannose content normally elevated during inflammation 
(Martinez-Pomares et al., 2001). Evidence in the literature suggests 
that M.tb may exploit its mannosylated cell surface components 
to survive within the host by binding the MR. In this context, we 
recently demonstrated that ManLAM/MR and higher-order PIMs/
MR phagocytic pathways lead to phagosome maturation arrest 
(Kang et al., 2005; Torrelles et al., 2006). Recognition of mannose 
residues by the MR has also been shown to reduce the microbi-
cidal activities of the macrophage by inhibiting the production 
of nitric oxide, oxygen radicals, and pro-inflammatory cytokines 
and by blocking M.tb-induced apoptosis through modifying Ca2+-
dependent signaling pathways (reviewed in Torrelles et al., 2008a). 
In addition, several studies have shown that ManLAM generates 
an anti-inflammatory response inhibiting the production of TNF 
and IL-12, and inducing the production of IL-10 and transform-
ing growth factor β (TGF-β; Astarie-Dequeker et al., 1999; Nigou 
et al., 2001; Chieppa et al., 2003). Recent studies have also estab-
lished an MR-specific signaling pathway in the pathogenesis of M.tb 
(Rajaram et al., 2010). Infection of human macrophages with viru-
lent M.tb or the addition of ManLAM up-regulates a transcription 
factor named peroxisome proliferator-activated receptor-gamma 
(PPAR-γ), an important molecule that regulates the macrophage Frontiers in Microbiology  |  Cellular and Infection Microbiology    January 2011  | Volume 2  | Article 2  |  6
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Conversely, SP-D opsonized M.tb that is phagocytosed undergoes 
increased phagosome–lysosome fusion resulting in limited intra-
cellular growth (Ferguson et al., 2006; Figure 2). Another soluble 
collectin considered in the establishment of M.tb infection is the 
MBL. MBL binds to M.tb promoting activation of the complement 
lectin pathway leading to C3bi deposition, as well as complement-
independent phagocytosis which induces pro-inflammation with 
the release of TNF, IL-1β, and IL-6 (reviewed in Dommett et al., 
2006; Figure 2). However, controversy regarding the model system 
(i.e., cell types and species specificity) studied still exists for deter-
mining if MBL is overall ultimately beneficial for M.tb or the host 
(Torrelles et al., 2008a).
other macrophage Surface receptorS
Other receptors (Figure 2) involved in M.tb recognition and inflam-
mation are CD14 (Khanna et al., 1996) and the scavenger receptors 
SR-A (Zimmerli et al., 1996), which participate in the uptake of 
non-opsonized bacilli by tissue-specific macrophages. However, 
their role in inflammation varies depending on the species-specific 
cell type used. Dectin-1, a β-glucan receptor, in combination with 
TLR2 has also been shown to participate in the immune response 
against M.tb by inducing TNF production in macrophages only 
infected with attenuated M.tb strains (Yadav and Schorey, 2006). 
Recently, macrophage-inducible C-type lectin (Mincle; Yamasaki 
et al., 2008) on the macrophage surface, has been shown to rec-
ognize M.tb trehalose dimycolate, and working together with the 
Fcγ receptor transmembrane segment induces pro-inflammation 
(Ishikawa et al., 2009; Schoenen et al., 2010). Conversely, Fcγ recep-
tors do not play a role in the phagocytosis of M.tb in the absence 
of specific antibody (Schlesinger et al., 1990).
cytoSolIc receptorS: nod2
Cytosolic regulators of the pro-inflammatory response known as 
nucleotide-binding oligomerization domain (NOD)-like receptors 
(Franchi et al., 2008) have been recently described to play a role 
during M.tb infection. NOD2, found in epithelial cells and APCs 
(Ogura et al., 2001; Gutierrez et al., 2002; Inohara and Nunez, 2003), 
regulates the production of inflammatory mediators in response 
to bacterial peptidoglycan components such as muramyl dipeptide 
(Inohara and Nunez, 2003). Human studies in patients infected 
with M.tb or M. leprae have linked a polymorphism in NOD2 to 
susceptibility to mycobacterial infections (Austin et al., 2008; Zhang 
et al., 2009). However, the role of NOD2 in the early stages of M.tb 
infection seems to be dependent on the model system studied. In 
this context, results obtained from in vitro and in vivo studies using 
the mouse model dispute the significance of NOD2 in controlling 
M.tb growth during the early stages of infection (Gandotra et al., 
2007; Divangahi et al., 2008). Conversely, in vitro studies using 
human macrophages infected with M.tb have established that, in 
accordance with the human polymorphism studies, NOD2 plays a 
role in controlling pro-inflammation and M.tb intracellular growth 
(Brooks et al., 2010; Figure 2). How NOD2 intersects with sig-
naling/trafficking networks is still unexplored. Although, NOD2 
can synergize with other signaling pathways like TLRs, enhancing 
pro-inflammation (Ferwerda et al., 2005), its capability to inter-
fere/associate  with  phagocytic  receptor  trafficking  networks  is 
not established. As cytosolic NOD2 appears to be associated with 
in the phagocytosis of M.tb (Fenton et al., 2005; Figure 2). C3 
deposition on M.tb happens quickly and is initiated by activation 
of the classical (in low serum concentrations) and/or alternative 
pathways (in high serum concentrations) via covalent linkages to 
M.tb surface targets in the forms of C3b and C3bi (Ferguson et al., 
2004). However, it is still unknown if C3 opsonization varies in 
form and amount among different stages of M.tb infection or tis-
sue sites. M.tb surface-exposed polysaccharides and lower-order 
PIMs (i.e., PIM2) have also been shown to interact directly with the 
lectin domain of CR3 (Villeneuve et al., 2005) and thus, presumably 
mediate M.tb uptake by macrophages. Although CR3 mediates both 
opsonic and non-opsonic uptake of M.tb by macrophages, its role 
during human infection remains unknown. In vitro and in vivo 
studies did not show an altered phenotype between CR3 deficient 
and wild-type mice in bacterial burden and pathology (Hu et al., 
2000). In this context, several studies have shown that CR4 is par-
ticularly abundant on cells that are involved in the uptake of M.tb 
leading to the conclusion that in the naïve host, CR4 may be the 
major player mediating M.tb uptake in the early stages of infection 
(Hirsch et al., 1994; Zaffran et al., 1998). This may correlate with the 
fact that CR4 and the MR are the most highly expressed receptors 
on AMs (Schlesinger et al., 2008).
collectInS and theIr SpecIfIc receptorS
There are three major collectins within the C-type lectin family that 
recognize specific sugar moieties on the M.tb surface increasing the 
interaction between the host and the bacteria. They are surfactant 
proteins (SP)-A and SP-D, and mannose binding lectin (MBL). 
SP-A and SP-D are mainly located in the lung, being secreted by 
alveolar epithelial type II cells into the surfactant (Wright, 2005). 
Various studies have provided evidence suggesting a dual role 
model for SP-A and SP-D, as they help maintain a balance between 
pro- and anti-inflammatory responses to M.tb in the lung environ-
ment. In this context, SP-A may be considered to be the perfect 
liaison for M.tb. Apart from being characterized for its capacity to 
act as an opsonin, a regulator for cell receptor activity enhancing 
phagocytosis by macrophages, and a mediator of inflammation by 
regulating the synthesis of ROIs and RNIs and cytokine secretion 
(reviewed in Torrelles et al., 2008a; Figure 2); recent studies show 
that SP-A may be a contributor to the establishment of a successful 
M.tb infection. In this context, SP-A is capable of opsonizing M.tb 
and after being recognized by its specific receptor, SP-R210, leads to 
the secretion of anti-inflammatory cytokines like IL-10 and TGF-β 
mediating suppression of cell-mediated immunity against M.tb 
(Samten et al., 2008). Linked to this, is the establishment that SP-A 
also up-regulates macrophage expression of the MR (a receptor that 
leads to M.tb intracellular survival within the macrophage by lim-
iting phagosome maturation; Beharka et al., 2002; Torrelles et al., 
2008a). SP-A also regulates TLR surface expression and activity in 
human macrophages (Henning et al., 2008), where despite its ability 
to specifically up-regulate TLR2 expression, SP-A seems to dampen 
TLR2 and TLR4 signaling in these cells, and thus situates SP-A 
as a critical mediator in regulating lung inflammatory responses 
through TLRs (Henning et al., 2008). SP-D has been recently shown 
to bind in high avidity to M.tb ManLAM and PIMs (Ferguson et al., 
1999; Carlson et al., 2009). SP-D opsonizes and subsequently aggre-
gates M.tb thereby reducing its phagocytosis (Ferguson et al., 1999). www.frontiersin.org  January 2011  | Volume 2  | Article 2  |  7
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be phosphorylated by a variety of stimuli leading to a cell type 
and stimulus-specific dependent production of chemokines (Roach 
and Schorey, 2002). NFκB, a key molecule in inflammation regu-
lation, is also involved in the regulation of chemokine gene tran-
scription (Mendez-Samperio, 2008) and subsequent secretion. In 
this context, specific heat-stable cell wall components of M.tb are 
described to induce chemokine secretion in specific cell types dif-
ferentially expressing defined receptors (Jones et al., 2001). This 
is the case for ManLAM, which induced chemokine secretion in 
monocytes, but not in AMs (Barnes et al., 1992). The fact that 
the MR, a major receptor for ManLAM, is present on AMs but 
not in monocytes, may favor ManLAM signaling through TLR2 
and TLR4 in monocytes leading to chemokine secretion. Recent 
contradictory studies also established a role for TNF as a control-
ler for chemokine secretion depending of the cell type and the 
mycobacterial strain (stimulus-specific) studied (Juffermans et al., 
1999; Mendez-Samperio et al., 2003). For example, chemokine pro-
duction induced by M. bovis BCG does not seem to be controlled 
by TNF (Mendez-Samperio et al., 2003), however, M.tb-infected 
macrophages reduce inflammatory chemokine secretion after TNF 
neutralization (Algood et al., 2004). The controversy also appears 
when the debate is who regulates who. Are cytokines regulat-
ing chemokines or contrary to the current view, are chemokines 
controlling the host response to infection? Kinetic studies closely 
evaluating levels of cytokines and chemokines in M.tb-infected 
host are necessary to address this issue. In this context, a recent 
study using M. bovis BCG showed that both cytokine and chem-
okine secretions seem to be tightly regulated, where a relationship 
between CCL2, CCL3, and TNF production exist in early stages of 
infection; and the same is described for CXCL10 and IL6 and IL10 
in intermediate phases, and for CCL22 and IFN-γ in late stages of 
infection (Mendez-Samperio, 2008). As CCL2 has been recently 
shown to inhibit the pro-inflammatory cytokine IL-12p40 during 
M.tb infection (Flores-Villanueva et al., 2005), the regulatory role 
of chemokines controlling inflammation may dictate the estab-
lishment and outcome of M.tb infection. Current literature sup-
porting this concept indicates that several chemokines trigger the 
activation of signaling cascades like MAPK/c-Jun N-terminal kinase 
(MAPK/JNK) and PI3K pathways associated with cell mitogenesis, 
chemotaxis, and cell activation (Mendez-Samperio, 2008). This is 
described for CCL2, which interacts with CCR2 activating different 
MAPK-ERK1/2 cascades involved in CCL2-associated cell immune 
responses against mycobacterial infections (Ashida et al., 2001). The 
importance of these regulatory pathways are emphasized in a recent 
study where MAPK-p38 and ERK1/2 activities can control intracel-
lular mycobacterial replication within the macrophage independ-
ently of TNF and/or IL-10 mediated effects (Klug et al., 2010).
Other members of the CXC chemokine family are also impli-
cated in controlling the inflammatory conditions following infec-
tion by M.tb. This is the case for CXCL1, CXCL7, CXCL8, CXCL9, 
and CXCL10 (reviewed in detail in Mendez-Samperio, 2008). In 
all cases, these CXC chemokines are, as in the case for CC chem-
okines, secreted depending on the stimulus and cell-type. Probably 
among the CXC chemokines CXCL8 (or IL-8) is the most studied 
in the regulation of M.tb infection. CXCL8 is secreted by different 
types of host cells in response to virulent M.tb infection recruiting 
inflammatory cells (i.e., neutrophils, lymphocytes, monocytes) to 
intracellular vesicles (Brooks et al., 2010), its role in triggering pro-
inflammation may depend on vesicular fusion events controlled 
during M.tb phagocytosis.
The outcome of M.tb infection and the subsequent inflamma-
tory response depends on the initial interaction(s) between M.tb 
and APCs. These interactions are mainly based on two factors: The 
nature and distribution of recognition receptors on the APC sur-
face, and on the biochemical nature of the cell wall constituents of 
the M.tb bacilli recognized by APCs. As described above, published 
studies define the role of each individual receptor (or a combina-
tion of them) during infection in vitro or in vivo using different 
means. It still is unclear though, which receptors and how many of 
them are involved in the initial M.tb–host interaction in vivo. Our 
in vitro studies using single cell suspensions of M.tb and human 
macrophages show that M.tb has a predilection for infection of 
specific subpopulations of APCs. Do these APC subpopulations 
preferentially express a specific receptor(s) beneficial for M.tb rec-
ognition/infection? Does the genetic background of the host (man) 
predispose for surface expression of specific receptors on APCs that 
favor M.tb infection? If the M.tb cell wall determines the impact 
of the infection; why do different virulent strains of M.tb present 
different motifs on their surface? Are biochemical differences on the 
M.tb cell wall surface favoring M.tb long term persistence within 
the host? Conversely, are we accounting for how disruption of a 
specific receptor alters the complex inflammatory network in vivo? 
Human studies addressing receptor polymorphisms in TB patients 
may help address these still unanswered questions.
chemokIneS In M.tb InfectIon
Due to their assistance in cell migration and subsequently granu-
loma formation, chemokines are essential but undefined players in 
the inflammatory response to M.tb infection. Their main function 
is to direct cell migration and immune homeostasis in the host. 
Current literature already has established a role for CC and CXC 
chemokines in the protective and immune host response to TB 
(reviewed in Mendez-Samperio, 2008). In vitro studies using M.tb-
infected murine and human cells demonstrate that CC chemokines 
like CCL2, CCL3, CCL4, CCL5, CCL19, CCL20, CCL21, and CCL22 
and their related chemokine receptors (i.e., CCR2 [for CCL2], 
CCR4 [for CCL2, CCL3, CCL5, and CCL22], CCR5 [for CCL2 
to CCL5], CCR6 [for CCL20], and CCR7 [for CCL19, CCL21]) 
regulate migration and activation of various immune cells like 
monocytes, macrophages, DCs and T lymphocytes by chemotaxis 
(Mendez-Samperio, 2008). In particular, the use of CCL5 deficient 
mice confirmed the role of this chemokine in M.tb infection. CCL5 
deficient mice infected with a low dose of aerosolized M.tb are 
described to present a decrease in recruitment of lymphocytes to 
TB granulomas site along with an impaired early acquired immu-
nity (Vesosky et al., 2010). Human studies involving bronchoal-
veolar lavage fluid and tissue from TB patients also demonstrate 
the involvement of CXCL8 (or IL-8), CCL2, and CCL5 during the 
acute phase of this disease (Kurashima et al., 1997).
Three major cellular receptor-dependent intracellular signaling 
pathways regulating chemokine secretion in response to mycobac-
terial infections have been described (reviewed in detail in Mendez-
Samperio, 2008). Mitogen-activated protein kinases (MAPKs) p38 
and extracellular signal-regulated kinases (ERK)1/2 are shown to Frontiers in Microbiology  |  Cellular and Infection Microbiology    January 2011  | Volume 2  | Article 2  |  8
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mycobacterial infection due to a delay and deficient granuloma 
formation leading to a widespread dissemination of M.tb (Bean 
et al., 1999; Jacobs et al., 2000). In this regard, TNF deficient mice 
are characterized for containing immature lymphocyte cells con-
centrated in the perivascular and peribronchial areas surrounding 
granulomas. Moreover, a deficiency in chemokine induction and 
cellular recruitment has also been established in this animal model 
system (Roach et al., 2002). Thus, disrupting the TNF balance leads 
to tissue damage and necrosis observed in many pathological fea-
tures of disseminated TB. This TNF balance is critical to maintain 
as other studies showed that continued presence of TNF has also 
growth promoting effects on M.tb (Byrd, 1997).
lymphotoxIn
Studies done so far have been inconclusive about the unique role 
played by lymphotoxin in the host immune response to M.tb. 
However, a recent study done using both conventional and neo-
free LT-α deficient mice indicates a non-essential role for LT-α in 
presence of unperturbed TNF expression in host defense to M.tb 
infection (Allie et al., 2010).
Il-12 famIly
This family is composed of IL-12p40 (homodimer with p40 + p40 
subunits), IL-12 or IL-12p70 (heterodimer with p40 + p35 subu-
nits), IL-23 (heterodimer with p40 + p19 subunits), and IL-27 
(heterodimer cytokine with Epstein–Barr virus-induced gene 3 
[EBI3 or IL-27B] + p28 [known as IL-30]). IL-12Rβ1/IL-12Rβ2 
complex is the receptor for IL-12, IL-12β1/IL-23R complex is the 
receptor for IL-23 while gp130/IL-27α complex is the receptor for 
IL-27 (Trinchieri et al., 2003; Hunter, 2005). Experimental models 
and human population studies have established that IL-12 plays 
an important role in both innate and adaptive responses against 
M.tb infection. IL-12 is shown to bind to its receptor IL-12R-β2 
and activate the JAK-STAT pathway inducing IFN-γ to differentiate 
CD4+ T cells in Th1 effectors (Mendez-Samperio, 2010). Recent 
studies established a great level of complexity on the IL-12 family 
cytokines in their involvement in the immunological control of 
M.tb infection (reviewed in detail in Cooper et al., 2007). IL-12 
is induced in macrophages and DCs after activation by microbial 
TLR ligands and other cytokines. Experiments using IL-12 deficient 
mice show an increase in bacterial burden and a drastic reduction 
in host survival (Flynn et al., 1995b; Cooper et al., 1997). These 
studies established IL-12 as a crucial cytokine in the development 
and maintenance of the type-1 cellular response to M.tb infec-
tion. IL-23 induces IL-17 production by memory T cells inducing 
the inflammatory response by Th17 cells (Khader and Cooper, 
2008). IL-23 like IL-12 generates protective cellular responses but 
at lesser degree, however, IL-27 is shown to moderate inflamma-
tion by inducing the early Th1 differentiation and generation of 
IL-10-producing regulatory T cells, which results in limited tissue 
destruction but subsequently limited bacterial control (Khader and 
Cooper, 2008). Thus, the IL-12 family is implicated in maintaining 
the balance between inflammation and bacterial killing to minimize 
tissue damage. A new role for IL-12p35 has been recently described, 
where this cytokine induces inflammation by suppressing TGF-β 
and stimulating NKT cells (Park et al., 2010). Other recent stud-
ies also support this new role showing that IL-12p35 alone also 
the infection site, and stimulating bactericidal non-oxidative mech-
anisms (Nibbering et al., 1993; Pace et al., 1999). Thus, chemokines 
triggered by M.tb infection regulate the innate immune events lay-
ing the foundation for the establishment of the subsequent host 
adaptive immune response.
decoy receptorS
These  rare  receptors  are  structurally  similar  to  conventional 
chemokine receptors but without the intrinsic capability to trig-
ger signaling events. Although only three of these receptors have 
been identified in mammals, D6 has been intensely studied due 
to its capacity to be recognized by multiple chemokines during 
inflammation (reviewed in Di et al., 2009). In this context, studies 
challenging D6 deficient mice with complete Freund’s adjuvant 
described an extensive inflammation characterized by leukocyte 
infiltration with localized areas of severe necrosis (Martinez de la 
et al., 2005). M.tb-infected D6 deficient mice presented a similar 
phenotype, also characterized by a substantial leukocyte infiltra-
tion causing vast local and systemic production and accumula-
tion of inflammatory chemokines and cytokines resulting in an 
overwhelming inflammation followed by severe tissue damage (Di 
et al., 2008). These findings support the initial concept that D6 is 
a receptor assisting with control of inflammation by scavenging 
circulating pro-inflammatory CC chemokines, but its action is 
dependent on the inflammatory conditions in the host environ-
ment. Another decoy receptor gaining interest in the field of TB 
research is Tir8. Tir8 is described to participate in the tight regula-
tion of the immune response by inhibiting TLR/IL-1 NFκB activa-
tion (Polentarutti et al., 2003). In vivo studies using Tir8 deficient 
mice showed that, like D6 deficient mice, Tir8 play a role in damping 
the immure response against M.tb infection (Di et al., 2009).
protectIve pro-Inflammatory medIatorS
Inflammation and immune reaction in response to most pathogens 
is partly mediated by a group of secreted polypeptides known as 
cytokines. Not only is the inflammatory response generated by 
cytokines against M.tb helping in the control of the infection, 
but they also play an important role during the chronic infection 
stage dictating the pathogenesis of the disease (Flynn and Chan, 
2001; Cooper, 2009). The fate of M.tb infection is determined by 
the interplay between various cytokines released at different time 
points of infection and the effect of these cytokines on the host 
cell and M.tb. In this section, we will present the main cytokines 
involved in chronic and cell-mediated inflammatory responses to 
M.tb infection.
tumor necroSIS factor
Tumor necrosis factor, an important component of innate immune 
mechanisms of the host against pathogens, is shown to be critical 
in the control of M.tb. TNF is an autocrine cytokine produced 
by macrophages, DCs and T cells, and performs functions like 
chemotaxis and granuloma formation. TNF, if not regulated can 
lead to tissue damage and cause immunopathology. The most 
widely studied models to understand the role of TNF in vivo are 
human TNF transgenic and TNF gene deficient mice. Studies using 
TNF and lymphotoxin-α (LT-α) deficient mice demonstrated that 
complete disruption of TNF and LT-α reduces host resistance to www.frontiersin.org  January 2011  | Volume 2  | Article 2  |  9
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in protective cellular immunity to TB infection, where cessation 
of bacterial growth directly correlates with the release of IFN-γ 
(Cooper et al., 1993).
other pro-Inflammatory cytokIneS
Other cytokines like IL-1, IL-6, IL-17, and IL-32 have been shown to 
be implicated to different degrees in M.tb infection control. IL-1β 
is a pro-inflammatory cytokine produced by monocytes, macro-
phages, DCs, B cells, and NK cells (Dinarello, 2009).
Interleukin-1β  up-regulates  essential  mediators  necessary 
for the control M.tb infection including iNOS and subsequent 
NO production (Chan et al., 2001), phagosomal acidification 
and  maturation  (Horsburgh  Jr.,  1991),  adhesion  molecules 
(Dinarello, 2009), and enzymatic activities like phospholipase 
A2 and cyclooxygenase (Hernandez-Pando et al., 2006; Yang et al., 
2009). Human studies (Gomez et al., 2006; Hawn et al., 2006; 
Settas et al., 2007) and in vivo studies using IL-1Ra (receptor 
antagonist) and IL-1α/IL-1β deficient mice (Juffermans et al., 
2000; Yamada et al., 2000; Fremond et al., 2007) established that 
the continuous effect of IL-1 is required for maintaining resist-
ance to M.tb infection. IL-6 is mainly considered to be a pro-
inflammatory cytokine involved in macrophage and cytotoxic 
T cell differentiation. Infection of IL-6 deficient mice with M.tb 
indicate that IL-6 is important for the control of M.tb infec-
tion, however, in humans it is considered a correlate for disease 
progression due to its role in inflammation and tissue damage 
(Appelberg, 1994; Ladel et al., 1997; Casarini et al., 1999; Tsao 
et al., 1999; Ilonidis et al., 2006).
Interleukin-17 is produced abundantly by Th17 CD4 T cells 
during early stages of M.tb infection (Lockhart et al., 2006). Studies 
using IL-17 deficient mice demonstrate that IL-17 is not essential 
to control M.tb infection, however, this cytokine plays a role in 
granuloma formation (Umemura et al., 2007). In this context, IL-17 
has been implicated in the recruitment of Th1 cells (Happel et al., 
2005; Khader et al., 2005; Wozniak et al., 2006), which produce anti-
gen-specific IFN-γ, and inhibit M.tb growth (Khader et al., 2007). 
Human studies show that IL-17 is produced by TB patients and 
IL-17 is also induced by BCG vaccination, however, its protective 
role against M.tb infection in human remains to be elucidated.
Interleukin-32 is a cell-associated proinflammatory cytokine, 
which  is  specifically  stimulated  by  mycobacteria  through  a 
caspase-1-  and  IL-18-dependent  production  of  IFNγ ( Netea 
et al., 2006).
Immunomodulatory cytokIneS
InterleukIn-10
Cell types producing IL-10 include monocytes, macrophages, 
DCs, regulatory CD4 T cells, and CD8 T cells (Sabat, 2010). The 
role of IL-10 is complicated to decipher as its regulatory proper-
ties depend on the cell type and infection model studied. For 
M.tb infection, IL-10 is thought to limit inflammation. In this 
scenario, IL-10 inhibits pro-inflammatory cytokines like IL-1, 
IL-6, IL-12, IL-18, and IFN-γ (Bogdan et al., 1991; de Waal Malefyt 
et al., 1991, 1993; Fiorentino et al., 1991; D’Andrea et al., 1993; 
Gruber et al., 1994; Aste-Amezaga et al., 1998); and chemokines 
like CCL3, CCL4, and CCL5 affecting cell recruitment, as well as 
blocking the generation of ROIs and NOIs (Bogdan et al., 1991; 
drives neutrophil and CD4+ T cell infiltrations by increasing the 
levels of CCL2, CXCL2, CXCL3, and the angiogenic factor vascular 
endothelial growth factor (VEGF; Frank et al., 2010). Recently, it has 
been shown that the p35 subunit of IL-12 is forming a heterodimer 
with EBI3 resulting in IL-35. IL-35 is defined as an IL-12 family 
cytokine that is produced only by regulatory T cells contributing 
to immune suppression (Collison et al., 2007). The role of IL-35 
in M.tb infection is still to be determined.
Interferon famIly
The IFN are a heterogeneous family of cytokines divided in type I 
and type II on basis of their structure, function, and cell of origin. 
While type I IFN (IFN-α and IFN-β) is secreted by various cell 
types and through innate immune receptors, type II (IFN-γ) is 
mainly produced as a result of stimulation of T lymphocytes and 
NK cells.
Type I IFN regulates different aspects of the immune response, 
inducing  cell-mediated  immunity.  Upon  infection  with  M.tb, 
immune cells and receptors induce the production of IFN-α and 
INF-β promoting the priming of CD8+ and CD4+ T cells (Cho 
et al., 2002; Remoli et al., 2002). The effect of IFN-α/β may be both 
favorable and unfavorable to the infected host cell. Studies using 
exogenous administration of IFN-α/β have shown that increased 
production of IFN-α/β could contribute to the host susceptibility 
to M.tb infection due to an overwhelming inflammatory response 
(Manca et al., 2001; Bouchonnet et al., 2002). However, a recent 
study has demonstrated that M.tb inhibits the production of IFN-
α/β in response to TLR9 signaling suggesting an evasion mecha-
nism to control the immune response against M.tb that is beneficial 
to the host by controlling an excessive immune response (Simmons 
et al., 2010).
Type II IFN-γ released by AMs, CD4 T cells, CD8 T cells, NKT 
cells, γδ T cells, and NK cells (Boehm et al., 1997; Fenton et al., 
1997; Wang et al., 1999; Vesosky et al., 2004) is considered as the 
key cytokine involved in the control of M.tb (Flynn and Chan, 
2001; Cooper, 2009). IFN-γ activates macrophages enhancing their 
production of pro-inflammatory cytokines, and up-  regulating 
their surface expression of cytokine/chemokine receptors, cos-
timulatory and adhesion molecules, and MHC-I and II molecules 
enhancing macrophage antigen presentation to T cells (Boehm 
et al., 1997). IFN-γ also controls cellular immunity by regulating 
T cell-mediated apoptosis (Li et al., 2007) as well as accumula-
tion of Th17 cells (Sher and Coffman, 1992), thus protecting the 
host from a massive T cell influx to the infection site. IFN-γ is 
defined as a correlate for host resistance to M.tb infection. In this 
scenario, antigen-specific IFN-γ is low in patients with clinical 
cases of active TB, when compared to latent TB (Zhang et al., 
1995; Lin et al., 1996). It has also been reported that individuals 
defective for IFN-γ or IFN-γ receptors (IFNGR) present increased 
susceptibility to infection with severe disease manifestations (de 
Jong et al., 1998), suggesting that insufficient IFN-γ is associated 
with TB disease progression. Two independent studies using a 
sub-lethal infection with M.tb showed that IFN-γ deficient mice 
failed to produce nitric oxide due to inadequate iNOS expression, 
and exhibited unrestricted bacterial growth and tissue necrosis 
with mice succumbing to disease faster (Cooper et al., 1993; 
Flynn et al., 1993). These studies prove the essentiality of IFN-γ Frontiers in Microbiology  |  Cellular and Infection Microbiology    January 2011  | Volume 2  | Article 2  |  10
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Overall, the local response to M.tb infection is defined by an 
initial intense pro-inflammatory response followed by the produc-
tion of anti-inflammatory mediators that serve to regulate tissue 
damage. Within this local environment M.tb battles to survive by 
interfering with the host inflammatory networks. It remains unclear 
whether the neutralization of anti-inflammatory mediators will 
benefit the host in contrast to the current goals of boosting Th1 
mediated protective immunity.
concluSIon remarkS
The interplay between M.tb and the host inflammatory response 
depends on many factors. From the bacterial side, M.tb strains dif-
fer in the cell wall components exposed on their surface. Virulent 
laboratory strains H37Rv and Erdman are defined to be hyperman-
nosylated on their surface; however, clinical isolates, some of them 
related to cases of hypervirulence and clinical outbreaks (i.e., 
HN878), present a more hydrophobic cell wall surface (Torrelles 
and Schlesinger, 2010). In this context, hypervirulent strains are 
characterized by the presence of other surface-exposed cell wall 
components (i.e., phenolic glycolipid, triacylglycerols), which 
regulate the cytokine response, and demonstrate rapid intrac-
ellular growth and marked tissue damage. These hypervirulent 
strains are associated with an unusual high proportion of active 
cases of disease and a high frequency of extrapulmonary disease. 
This has been directly attributed to host immune subversion. In 
contrast, M.tb strain CDC1551 is related to a low number of cases 
of active disease, followed by an unusually high rate of seroconver-
sion, inducing a more rigorous immunologic response (reviewed 
in Torrelles and Schlesinger, 2010). Even within the same M.tb 
strain, it is likely not the case that all bacilli are identical replicas, 
and thus bacilli may differentially interact with the host. Thus, 
at an M.tb infection site we may find a mixture of events, where 
simplistically speaking, depending on its cell wall surface pheno-
type an M.tb bacillus may interact with a host cell receptor trig-
gering pro-inflammation that promotes bacterial killing, or may 
interact with a host cell receptor triggering anti-inflammation 
and bacterial intracellular survival. From the host (man) perspec-
tive, genetic predisposition and environmental living conditions 
dictate the predilection for an M.tb infection. Even in the context 
of the same host (man) and within the same host cell population, 
differences between host cells in receptor expression, signaling and 
innate and adaptive immune functions exist (and we can extend 
these differences to the different model systems used to study M.tb 
infection in vitro and in vivo). Moreover, within the same host 
cell population (i.e., AMs), there are likely to be different host 
cell subpopulation(s) that differentially trigger the inflammatory 
response (i.e., AMs expressing more TLR2 vs. AMs expressing 
more MR). With these questions in mind, is the establishment 
of a successful M.tb infection just a question of chance or are we 
looking at the evolutionarily developed perfect storm of elements? 
In this review we have presented the major players involved in 
the tight regulation of the inflammatory response during M.tb 
infection. Some favor infection and others do not. However, upon 
the successful establishment of an M.tb infection, the ultimate 
goal of the host is to reduce inflammation and tissue destruc-
tion, and in this scenario, M.tb has learned to survive. Efforts to 
define the M.tb cell wall components produced in vivo as well as 
Cunha et al., 1992; Niiro et al., 1992; Cenci et al., 1993; Kuga 
et al., 1996; Roilides et al., 1997) that are important for M.tb con-
trol. In this process IL-10 is thought to work by interfering with 
intracellular signaling cascades such as suppressor of cytokine 
signaling-3 (SOCS3; Cassatella et al., 1999) and NFκB (Wang 
et al., 1995; Romano et al., 1996; Schottelius et al., 1999; Berrebi 
et al., 2003). IL-10 is also implicated in blocking antigen process-
ing and presentation in different APCs, therefore diminishing 
T cell responses (Moore et al., 2001). Experimental data using the 
mouse model show that IL-10 alone plays a pivotal role during 
the chronic/latent stage of pulmonary TB potentially contributing 
to TB reactivation (Turner et al., 2002; Beamer et al., 2008). In 
this context, induction of IL-10 may be considered as prevent-
ing tissue damage during chronic M.tb infection. Studies using 
transgenic mice support this funding where induction of IL-10 is 
considered to prevent tissue damage but also contributes to M.tb 
growth (Murray et al., 1997). Studies using IL-10 deficient mice 
show no effect (North, 1998) or a protective effect when IL-10 is 
absent, which is also supported by studies blocking the action of 
IL-10 receptor (Beamer et al., 2008; Redford et al., 2010). These 
murine studies are supported by recent human population studies 
where presence of IL-10 correlates with susceptibility to myco-
bacterial infections (Boussiotis et al., 2000; de la Barrera et al., 
2004). Recent in vitro reports suggest that IL-10 may interfere with 
M.tb persistence by stalling phagosome maturation in human 
macrophages (O’Leary et al., 2010). Thus, the benefits of IL-10 are 
controversial, as at the same time that IL-10 seems to limit tissue 
damage by suppressing inflammation, IL-10 also contributes to 
the host environment that allows M.tb to persist, and thus IL-10 
directly contributes to reactivation of TB.
tranSformIng growth factor β
Transforming growth factor β is defined as a pluripotent cytokine 
that modulates the immune response by down-regulating acquired 
immunity and de-activating macrophages. TGF-β is secreted by 
a large number of cell types including monocytes, macrophages, 
DCs, and CD4+ regulatory T cells (Aung et al., 2005; Latchumanan 
et al., 2005). TGF-β is shown to synergize with IL-10 to promote 
immune tolerance and limit pathological inflammation (Oswald 
et al., 1992; Zeller et al., 1999; Clegg and Hughes, 2002; Chen et al., 
2003). Similar to IL-10, TGF-β also suppresses APCs costimulatory 
molecules (Strobl and Knapp, 1999), NOS production, and indi-
rectly down-regulates T cell function and proliferation by inhibiting 
cytokine production (Lee et al., 1997; Nakao et al., 1997; Bright 
and Sriram, 1998; Gorham et al., 1998). Studies have shown up-
regulation of TGF-β in monocytes and macrophages in granuloma 
from patients with active TB (Toossi et al., 1995), and high levels 
of TGF-β is directly associated with severe stages of the disease. 
As TGF-β is considered an anti-inflammatory cytokine that helps 
to reduce the harmful inflammatory effects associated with T cell 
immunity to M.tb infection, regulating TGF-β effects may be criti-
cal to control M.tb infection. In this scenario, using TGF-β blockers 
like latency associated protein (Saharinen and Keski-Oja, 2000) and 
decorin (Hildebrand et al., 1994), which form inactive complexes 
with TGF-β should reduce TGF-β anti-inflammatory effects on T 
cells and macrophages, and may be a way to control inflammation 
and prevent M.tb infection spread.www.frontiersin.org  January 2011  | Volume 2  | Article 2  |  11
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